Gonadotropin-releasing Hormone Agonist

Aka: Gonadotropin-releasing Hormone Agonist, GnRH agonist, Nafarelin Acetate, Synarel

II. Indication

  1. Endometriosis

III. Pathophysiology

  1. Potentiates Gonadotropin-releasing hormone (GnRH)
  2. Results in hypoestrogenism or pseudo-Menopause
  3. Does not cause the same androgenic effects as Danazol

IV. Dosing: Nafarelin Acetate (Synarel)

  1. Synarel 200-400 micro-g intranasally bid

V. Efficacy

  1. Effective at regression of lesions and relief of pain
  2. No proven effect on fertility

VI. Adverse effects

  1. Menopausal symptoms
    1. Hot Flashes
    2. Insomnia
    3. Emotional changes
  2. Bone density loss with prolonged use

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Gonadotropin-releasing Hormone Agonist." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Ontology: Synarel (C0131793)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH D017274
French Synarel
English synarel, Synarel
Norwegian Synarel
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

2021 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo